Merck, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: $295.3B

Website: http://www.merck.ph

Clinical Trials

Single Dose Study of MK-2060 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Older Japanese Participants on Dialysis (MK-2060-012)

Phase 1

Completed

Conditions: End-Stage Renal Disease (ESRD)
End-Stage Kidney Disease (ESKD)
Kidney Failure, Chronic

Interventions: Biological: MK-2060
Drug: Placebo

First Posted Date: 2023-03-15

Last Posted Date: 2025-03-14

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 17

Registration Number: NCT05769595

Locations: 🇯🇵
Jomo Ohashi Clinic ( Site 1210), Maebashi, Gunma, Japan
🇯🇵
Keiaikai Nakamura Hospital ( Site 1213), Beppu, Oita, Japan
🇯🇵
Kasugai Municipal Hospital ( Site 1203), Kasugai, Aichi, Japan

and more 9 locations

A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)

Phase 3

Active, not recruiting

Conditions: HIV Infection

Interventions: Drug: DOR/ISL

First Posted Date: 2023-03-13

Last Posted Date: 2024-11-08

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 650

Registration Number: NCT05766501

Locations: 🇺🇸
Mills Clinical Research ( Site 3114), Los Angeles, California, United States
🇨🇦
Maple Leaf Research ( Site 1301), Toronto, Ontario, Canada
🇺🇸
Kaiser Permanente ( Site 3124), Los Angeles, California, United States

and more 92 locations

A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045)

Phase 3

Completed

Conditions: Cytomegalovirus Infection

Interventions: Drug: Letermovir

First Posted Date: 2023-03-10

Last Posted Date: 2025-03-25

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 120

Registration Number: NCT05763823

Locations: 🇨🇳
Institute of hematology&blood disease hospital-Hematology ( Site 0030), Tianjin, Tianjin, China
🇨🇳
Shenzhen Second People's Hospital-Hematology Department ( Site 0006), Shenzhen, Guangdong, China
🇨🇳
The First Affiliated Hospital of Soochow University-hematology department ( Site 0029), Suzhou, Jiangsu, China

and more 18 locations

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)

Phase 3

Active, not recruiting

Conditions: Metastatic Non-small Cell Lung Cancer

Interventions: Biological: Pembrolizumab (+) Berahyaluronidase alfa
Drug: Pemetrexed
Drug: Cisplatin
Drug: Carboplatin
Drug: Paclitaxel
Drug: Nab-paclitaxel
Biological: Pembrolizumab
Drug: Filgrastim
Drug: Pegylated filgrastim

First Posted Date: 2023-02-10

Last Posted Date: 2025-01-31

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 377

Registration Number: NCT05722015

Locations: 🇭🇺
Törökbálinti Tüdőgyógyintézet ( Site 2105), Törökbálint, Pest, Hungary
🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 4207), Kaohsiung, Taiwan
🇺🇸
St. Joseph's Hospital and Medical Center-Dignity Health Cancer Institute ( Site 0023), Phoenix, Arizona, United States

and more 107 locations

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

Phase 2

Recruiting

Conditions: Left Ventricular Systolic Dysfunction
Heart Failure

Interventions: Drug: Vericiguat tablet
Drug: Placebo tablet
Drug: Vericiguat suspension
Drug: Placebo suspension

First Posted Date: 2023-02-06

Last Posted Date: 2025-05-16

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 342

Registration Number: NCT05714085

Locations: 🇺🇸
Loma Linda University Health System ( Site 0008), Loma Linda, California, United States
🇺🇸
The Regents of the University of California - Los Angeles (UCLA Pediatrics) ( Site 0002), Los Angeles, California, United States
🇺🇸
Children's Hospital Colorado ( Site 0012), Aurora, Colorado, United States

and more 88 locations

DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

Phase 3

Active, not recruiting

Conditions: HIV-1 Infection

Interventions: Drug: DOR/ISL
Drug: BIC/FTC/TAF
Drug: Placebo to BIC/FTC/TAF
Drug: Placebo to DOR/ISL

First Posted Date: 2023-01-30

Last Posted Date: 2024-10-21

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 500

Registration Number: NCT05705349

Locations: 🇺🇸
Pueblo Family Physicians ( Site 5674), Phoenix, Arizona, United States
🇺🇸
Pacific Oaks Medical Group ( Site 5681), Beverly Hills, California, United States
🇺🇸
Ruane Clinical Research Group, Inc ( Site 5658), Los Angeles, California, United States

and more 128 locations

MK-8510 Monotherapy for the Treatment of Anti-retroviral naïve Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8510-002)

Phase 1

Withdrawn

Conditions: Immunodeficiency Virus Type 1, Human
HIV-1
Human Immunodeficiency Virus 1
Human Immunodeficiency Virus Type 1

Interventions: Drug: MK-8510

First Posted Date: 2023-01-26

Last Posted Date: 2023-03-27

Lead Sponsor: Merck Sharp & Dohme LLC

Registration Number: NCT05700734

Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)

Phase 3

Completed

Conditions: Pneumococcal Infection

Interventions: Biological: V116
Biological: PCV15
Biological: Placebo
Biological: PPSV23

First Posted Date: 2023-01-25

Last Posted Date: 2025-02-26

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 518

Registration Number: NCT05696080

Locations: 🇨🇱
Centro de Investigación del Maule-Centro de Investigación 2 ( Site 1010), Talca, Maule, Chile
🇨🇦
Clinique de médecine Urbaine du Quartier Latin ( Site 0111), Montreal, Quebec, Canada
🇺🇸
Mid Hudson Medical Research ( Site 0008), New Windsor, New York, United States

and more 41 locations

A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002)

Phase 1

Active, not recruiting

Conditions: Mature B-cell Neoplasms

Interventions: Drug: Nemtabrutinib

First Posted Date: 2023-01-06

Last Posted Date: 2024-01-26

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 12

Registration Number: NCT05673460

Locations: 🇯🇵
National Cancer Center Hospital East ( Site 0002), Kashiwa, Chiba, Japan
🇯🇵
Kyushu University Hospital ( Site 0008), Fukuoka, Japan
🇯🇵
Chiba Cancer Center ( Site 0005), Chiba, Japan

and more 4 locations

A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

Phase 3

Active, not recruiting

Conditions: Melanoma

Interventions: Biological: Pembrolizumab/Vibostolimab
Biological: Pembrolizumab

First Posted Date: 2022-12-27

Last Posted Date: 2025-04-30

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1594

Registration Number: NCT05665595

Locations: 🇦🇷
Clinica Adventista Belgrano-Oncology ( Site 0211), Caba, Argentina
🇨🇳
West China Hospital, Sichuan University-Head and Neck Oncology ( Site 1667), Cheng Du, Sichuan, China
🇺🇸
The Angeles Clinic and Research Institute - West Los Angeles Office ( Site 0123), Los Angeles, California, United States

and more 202 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy